Maxim gives a bullish call on Gilead Sciences (GILD +1.8%) today, doubling is price target to $97 from $48. The firm says that recent estimates from private surveys put the Hepatitis C market in Japan much higher than previously thought, perhaps as high as 2M infections. Separately, Morgan Stanley also upped its target on higher HCV estimates as well, but to a much more modest $65 from $46. [View news story]
the stock split doubling his shares - it makes sense to take profits when it goes back up after the split - in this situation it was for profits i'm sure
T-Mobile USA (DTEGY.PK) will start selling the iPhone 5 (AAPL) on April 12. In tune with the carrier's embrace of subsidy-free plans, the 16GB model will be sold without contract for an up-front cost of $100 and a 2-year, $20/month installment schedule (total cost of $580, a little below the phone's unlocked price of $649). T-Mobile, which is (finally) launching a 4G LTE network in 7 cities, will also sell the BlackBerry Z10 (BBRY) and Samsung's Galaxy S IV. The carrier plans to offer 4G coverage to 100M people by mid-year, and 200M by year's end. (live blog) (PR) [View news story]
Velti (VELT -15.4%) can't catch a break; shares are now down 34% since the mobile ad agency badly missed Q4 estimates and issued light guidance. Jefferies' Peter Misek, who cut shares to Hold in response, notes Velti has violated its debt covenants and thinks "going concern" issues now exist. Janney's Richard Fetyko considers it hard to determine how much of Velti's revenue comes from paying customers in light of its collection issues, and observes the company had $56M in cash and $47M in debt as of early Q1. [View news story]
This pos doesn't deserve a break - it should go BK soon -
Data from Phase 3 Studies of Gilead’s Sofosbuvir for Hepatitis C [View article]
Maxim gives a bullish call on Gilead Sciences (GILD +1.8%) today, doubling is price target to $97 from $48. The firm says that recent estimates from private surveys put the Hepatitis C market in Japan much higher than previously thought, perhaps as high as 2M infections. Separately, Morgan Stanley also upped its target on higher HCV estimates as well, but to a much more modest $65 from $46. [View news story]
long gild
Tuesday Options Brief: SFD, ELLI & GILD [View article]
I can't wait till it skyrockets
Can Gilead Maintain Its Momentum? [View article]
Can Gilead Maintain Its Momentum? [View article]
Long GILD - hope it doubles- that would be fab
Velti: Serial Underachiever Continues To Disappoint [View article]
Molycorp Hits 52 Week Low - 'The Pain' Is Real [View article]
Quescor: Trading Based On Negative Speculations Rather Than Positive Financials [View article]
careful backing the truck up
Velti: Serial Underachiever Continues To Disappoint [View article]
Gilead Sciences: Stribild Recommended, Great Long-Term Hold [View article]
T-Mobile USA (DTEGY.PK) will start selling the iPhone 5 (AAPL) on April 12. In tune with the carrier's embrace of subsidy-free plans, the 16GB model will be sold without contract for an up-front cost of $100 and a 2-year, $20/month installment schedule (total cost of $580, a little below the phone's unlocked price of $649). T-Mobile, which is (finally) launching a 4G LTE network in 7 cities, will also sell the BlackBerry Z10 (BBRY) and Samsung's Galaxy S IV. The carrier plans to offer 4G coverage to 100M people by mid-year, and 200M by year's end. (live blog) (PR) [View news story]
Morgan Stanley selects 20 stocks for the long term, based on "competitive advantages, business model, pricing power, cost efficiency and growth": AMZN, AMT, BLK, CPN, CP, CVX, COST, EL, GILD, HON, JPM, LTD, MON, NWSA, PM, RPM, SBUX, SYMC, TMO, WMB. [View news story]
Velti (VELT -15.4%) can't catch a break; shares are now down 34% since the mobile ad agency badly missed Q4 estimates and issued light guidance. Jefferies' Peter Misek, who cut shares to Hold in response, notes Velti has violated its debt covenants and thinks "going concern" issues now exist. Janney's Richard Fetyko considers it hard to determine how much of Velti's revenue comes from paying customers in light of its collection issues, and observes the company had $56M in cash and $47M in debt as of early Q1. [View news story]
Don't collect your money!! Just give it away!
Velti Plc Management Discusses Q4 2012 Results - Earnings Call Transcript [View article]
Controversial Questcor Still Looks Like A Buy [View article]